Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Brian T. Powl Insider Profile
4 Followers
Brian T. Powl, CCO at Fate Therapeutics, holds 59.67K shares in Kura Oncology (Ticker: KURA), holds 41.15K shares in Fate Therapeutics (Ticker: FATE). Most recently, Brian T. Powl Sold ― shares of Kura Oncology on Jan 28, 2025 for an estimated value of 12.46K.
Brian T. Powl has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Most Profitable Insider Trade
The most profitable trade made by Brian T. Powl
Brian T. Powl's Trading History
Fate Therapeutics
Jul 06, 2023
CCO
Informative Sell
18.77K
$53.90K
Kura Oncology
Jan 28, 2025
CCO
Informative Sell
12.46K
$458.84K
List of latest transactions for each holding click on a transaction to see Brian T. Powl's performance on stock
You May Also Like
Brian T. Powl insider profile FAQ
What is the percentage of profitable transactions made by Brian T. Powl?
The percentage of profitable transactions made by Brian T. Powl is ―.
What is the average return per transaction made by Brian T. Powl?
The average return per transaction made by Brian T. Powl is ―.
What stocks does Brian T. Powl hold?
Brian T. Powl holds: FATE, KURA stocks.
What was Brian T. Powl’s latest transaction?
Brian T. Powl latest transaction was an Informative Sell of $12.46K.
What was Brian T. Powl's most profitable transaction?
Brian T. Powl’s most profitable transaction was an Informative Sell of FATE stock on July 6, 2023. The return on the trade was 32.10%.
What is Brian T. Powl's role in Fate Therapeutics?
Brian T. Powl's role in Fate Therapeutics is CCO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.